Navigation Links
ATS Medical Announces Participation in 45th Annual Society of Thoracic Surgeons Meeting

MINNEAPOLIS, Jan. 22 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced its participation in the 45th Annual Meeting of the Society of Thoracic Surgeons (STS) and related company-sponsored events. The meeting runs January 24-28, 2009, in San Francisco, California, and serves as one of the year's key gatherings of cardiovascular surgeons from around the world.


ATS Medical continues to expand its cardiac surgery product portfolio, and this meeting provides an excellent opportunity to display its array of offerings for heart valve therapy and surgical ablation of cardiac arrhythmias. The ATS CryoMaze(TM) system for surgical cryoablation will be prominently featured. Surgical treatment of cardiac arrhythmias is a topic of great interest for surgeons and increasing numbers find the ATS CryoMaze system to be their product of choice. ATS is sponsoring "Frontiers in Cryoablation," a symposium designed to provide a unique forum for sharing experiences among physician attendees. ATS Medical's Cryoablation Scientific Advisory Board members will lead the open discussion in a question and answer format. The symposium will be held on Sunday, January 25th at 7:00 pm at the Marriott San Francisco.

The ATS exhibit will also focus on the company's flagship ATS Open Pivot(R) mechanical heart valve franchise, including its newest iteration, the ATS Open Pivot(R) AP360(TM), as well as its newly-approved ATS 3f(R) Aortic Bioprosthesis tissue valve. The AP360(TM) valve's unique open pivot design results in exceptional performance and a low risk profile while the ATS 3f(R) Aortic Bioprosthesis, whose design is based on the precept that "Form Follows Function," is a revolutionary next generation stentless pericardical aortic tissue valve that is unlike any other. Post-approval commercialization of the ATS 3f Aortic Bioprosthesis continues with the valve's unique design and compelling clinical benefits generating enthusiasm and product demand among U.S. surgeons.

The ATS Simulus(R) annuloplasty product line, also featured in ATS' exhibit, has expanded to include flexible and semi-rigid offerings. ATS Medical will co-sponsor a symposium entitled "Future-Proof Your Practice With Technologies Available Now" where respected surgeons will discuss the integration of new techniques to improve cardiac procedures. Daniel Bethencourt, M.D., Long Beach Memorial Hospital, will include his experience with ATS Simulus products during his presentation entitled "Modernized Valve Repair-Techniques, Approaches, and Rings". This symposium will be held on Saturday, January 24th at 6:30 pm at the W Hotel, San Francisco.

Hands-on demonstrations of all the unique technologies from ATS Medical will be available at the ATS Medical booth #809.

About ATS Medical

ATS Medical, Inc. is dedicated to 'Advancing The Standards' of cardiac surgery through the development, manufacturing and marketing of innovative products and services for the treatment of structural heart disease. ATS Medical serves the cardiac surgery community by focusing on two distinct but operationally synergistic market segments: heart valve disease therapy and surgical ablation of cardiac arrhythmias.

ATS was originally founded to develop the ATS Open Pivot(R) Heart Valve as a new mechanical heart valve standard of care. Today the Open Pivot heart valve is the preferred mechanical heart valve in many markets around the world and the fastest growing mechanical prosthesis in the market. Building on this legacy and addressing the largest market segment in heart valve therapy, the ATS 3f(R) brand encompasses an innovative tissue heart valve portfolio to address conventional open surgery requirements as well as the growing demand for less invasive, sutureless based procedures. The ATS 3f(R) portfolio includes offerings at various stages including early product development, pivotal clinical trials, and market commercialization. Completing the portfolio in heart valve therapy is the ATS Simulus(R) annuloplasty product line. Simulus products assist the surgeon in repairing a patient's native heart valve as an alternative to replacement. Continuing ATS Medical's focus on serving the cardiac surgery community are the ATS CryoMaze(TM) products for surgical cryoablation of cardiac arrhythmias. ATS CryoMaze(TM) products are used by surgeons to treat patients suffering from cardiac arrhythmias, the largest and fastest growing form of structural heart disease in populations over 60 years of age. The ATS Medical web site is

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including the results of clinical trials, the timing of regulatory approvals, the integration of 3f Therapeutics and the surgical cryoablation business of CryoCath Technologies, Inc., regulatory actions, competition, pricing pressures, supplier actions and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2007 and its most recent quarterly report on Form 10-Q.

SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Turner Selected to Construct Replacement Hospital for University Medical Center at Princeton
2. Nurses Often Left Out of Medical Error Talks
3. Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group
4. B. Braun Medical Inc. Launches Home Infusion Therapy Web Site
5. Natural TMJ Relief(R) Gains Momentum in the Medical Marketplace
6. China Medical Technologies Announces the Receipt of SFDA Approval for Two of its FISH Probes and the Approval for the Hi-Tech Enterprise Status for its PRC Subsidiaries
7. Medical Management Corporation Updates Medical Billing Services
8. University Medical Pharmaceuticals Appoints Tom Roche as Senior Vice President, Global Sales and Marketing
9. USC awarded $22.2M NIH national biomedical informatics infrastructure coordinating center contract
10. Houston Northwest Medical Center Is One of Two Hospitals in Texas Named A Mentor Hospital for Heart Attack
11. American Heart Association 2008 Wrap-Up Report: Top Research Advances Include Studies That Influence Medical Care, Apply Science To Real World Communities
Post Your Comments:
(Date:11/26/2015)... ... November 26, 2015 , ... ... Travel Representative. As a franchise owner, Somu now offers travelers, value and care ... wedding packages, private cruise sales, as well as, cabin upgrades and special amenities ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories ... and offered by healthcare staffing agency Aureus Medical Group . These ... October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... Mass. (PRWEB) , ... November 26, 2015 , ... ... thorough second medical opinion process, participated in the 61st annual Employee Benefits Conference. ... Plans and took place Sunday, November 8th through Wednesday, November 11th, 2015. The ...
(Date:11/26/2015)... ... November 26, 2015 , ... Health-E-minds ... collaborated with Women’s Web – an online resource for Indian women looking ... and emotional well-being relationship, life balance, stress, professional development, and lifestyle. Health-E-minds ...
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology: